title: Response to: Tocilizumab, neuromyelitis optica (NMO), and multiple sclerosis.
authors.affiliation: Hôpital de l'Enfant-Jésus, CHU de Québec, Département des sciences neurologiques, Université Laval, Québec City, QC, Canada philippe.beauchemin.1@ulaval.ca.|UBC Hospital MS Clinic, Department of Neurology, University of British Columbia (UBC), Vancouver, BC, Canada.
authors.forename: Philippe
authors.initials: P
authors.lastname: Beauchemin
authors.affiliation: UBC Hospital MS Clinic, Department of Neurology, University of British Columbia (UBC), Vancouver, BC, Canada.
authors.forename: Robert
authors.initials: R
authors.lastname: Carruthers
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies; D006801:Humans; D009103:Multiple Sclerosis; D009471:Neuromyelitis Optica
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies; C502936:tocilizumab